Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.

Wei ZhaiSaiyang LiJin ZhangYonghui ChenJunjie MaWen KongDongkui GongJunhua ZhengWei XueYunfei Xu

Published in: Molecular cancer (2018)

Our study presented a road map for targeting this newly identified miR-452-5p and its SMAD4/SMAD7 signals pathway, which imparted a new potential therapeutic strategy for mRCC treatment.

Keyphrases

transforming growth factor
epithelial mesenchymal transition
signaling pathway
papillary thyroid
renal cell carcinoma
cancer therapy
childhood cancer
metastatic renal cell carcinoma